SOLV
SolventumNYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-05-08
As of May 8, 2026, SOLV has a composite score of 30.4 and a signal label of "favorable." This change from "mild_favorable" to "favorable" is driven by a significant increase in the company momentum score, which rose by 101.0 points to 61.2, and a 19.3 point increase in the composite insight score to 30.4, both following fresh earnings. The analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.29
- Slope (norm)-0.39
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Why this setup
EPS estimate $1.66 → $1.90 (+14.4% / 30d). 1 raised, 0 cut, 10 covering analysts.
0 upgrades, 0 downgrades / 30d, 7 maintained. 43% of analysts rate Buy.
5 PT revisions / 30d. Avg target 28.4% above current price.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
2 material events in the last 24 months — top 2 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Achieve organic sales growth of 2.0% to 3.0% in 2026growthbehind0% progress
2/26: “Solventum is affirming its full year 2026 guidance: Organic sales growth of +2.0% to +3.0%.”
Why this status
Stated in 2 of last 2 quarters. Solventum's guidance for 2026 targets organic sales growth of 2.0% to 3.0%. Revenue was $1.998B in 2025-Q4, down from $2.074B in 2024-Q4, indicating a need for growth. Persistent statement, limited substantive delivery this quarter.
- 2.Maintain adjusted EPS guidance of $6.40 to $6.60 for 2026growthbehind0% progress
5/5: “Adjusted EPS will be toward the high end of existing $6.40 to $6.60 guidance range.”
Why this status
Stated in 2 of last 2 quarters. Solventum's adjusted EPS guidance for 2026 is $6.40 to $6.60. Diluted EPS was $7.22 in 2025-Q3, indicating a strong prior performance. Recurring focus, narrow delivery so far.
- 3.Achieve free cash flow of ~$200M for 2026capital allocationmixed30% progress
5/5: “Free cash flow of ~$200M.”
Why this status
Stated in 2 of last 2 quarters. Solventum's free cash flow target for 2026 is ~$200M. Operating cash flow was $271M in 2025-Q4, showing a positive cash generation trend. Recurring focus, narrow delivery so far.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 28%; 252d 28%.
Drawdown — Max 1y −27%. Bad day move −3%.
Beta to sector ETF (XLV) — 0.82 over 1y.
Liquidity — score 98/100.
Sub-scores — vol 53/100, drawdown 45/100, beta 82/100, earnings vol —.
Calm + bullish setup — clean pre-earnings positioning pattern.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- earnings refresh · company_momentum_scoreseverity 100
Company momentum rose by 101.0 points (from -39.8 to 61.2) after fresh earnings.
- earnings refresh · composite_insight_scoreseverity 39
Composite insight rose by 19.3 points (from 11.1 to 30.4) after fresh earnings.
- earnings refresh · signal_labelseverity 20
Signal changed from 'mild_favorable' to 'favorable' after fresh earnings.
As of 2026-05-08, the company momentum score for SOLV rose by 101.0 points, from -39.8 to 61.2, and the composite insight score increased by 19.3 points, from 11.1 to 30.4, following fresh earnings. Additionally, the signal label changed from 'mild_favorable' to 'favorable' after the earnings update.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Achieve organic sales growth of 2.0% to 3.0% in 2026
GrowthSolventum aims for organic sales growth of 2.0% to 3.0% for the full year 2026, excluding SKU exit impacts.
BehindStated in 2 of last 2 quarters. Solventum's guidance for 2026 targets organic sales growth of 2.0% to 3.0%. Revenue was $1.998B in 2025-Q4, down from $2.074B in 2024-Q4, indicating a need for growth. Persistent statement, limited substantive delivery this quarter.
0%CEO/CFO:“Solventum is affirming its full year 2026 guidance: Organic sales growth of +2.0% to +3.0%.”Press releaseSource dated 2026-02-26Stated 2 of last 8 quartersFirst seen 2026-02-26Show history (2)
- 2025-Q4Press release
“Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidance.”
- 2025-Q3Multiple sources
“Expects full year organic sales growth to be at the high end of +2.0% to +3.0% range.”
- #2
Maintain adjusted EPS guidance of $6.40 to $6.60 for 2026
GrowthNew since 2026-05-05Solventum aims to achieve adjusted EPS toward the high end of the $6.40 to $6.60 range for 2026.
BehindStated in 2 of last 2 quarters. Solventum's adjusted EPS guidance for 2026 is $6.40 to $6.60. Diluted EPS was $7.22 in 2025-Q3, indicating a strong prior performance. Recurring focus, narrow delivery so far.
0%CEO/CFO:“Adjusted EPS will be toward the high end of existing $6.40 to $6.60 guidance range.”Press releaseSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05Show history (2)
- 2025-Q4Press release
“Adjusted EPS of $6.40 to $6.60.”
- 2025-Q3Multiple sources
“Increases full year adjusted earnings per share outlook to $5.98 to $6.08.”
- #3
Achieve free cash flow of ~$200M for 2026
Capital allocationNew since 2026-05-05Solventum targets free cash flow of approximately $200 million for the full year 2026.
MixedStated in 2 of last 2 quarters. Solventum's free cash flow target for 2026 is ~$200M. Operating cash flow was $271M in 2025-Q4, showing a positive cash generation trend. Recurring focus, narrow delivery so far.
30%CEO/CFO:“Free cash flow of ~$200M.”Press releaseSource dated 2026-05-05Stated 2 of last 8 quartersFirst seen 2026-05-05Show history (2)
- 2025-Q4Press release
“Free cash flow of ~$200M.”
- 2025-Q3Multiple sources
“Revised free cash flow to a range of $150M to $250M.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
P/E over the last 5 years
26 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
SOLV Solventum | +30 | inexpensive | moderate |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently REAFFIRMED as of 2026-05-05)+4.0 pts
- If next-quarter guidance is cut (currently REAFFIRMED as of 2026-05-05)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-053d agoItem 2.02
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Wayde McMillan Wayde McMillan Executive Vice President and Chief Financial Officer (Principal Financial Officer) Dated: May 5, 2026
earnings preannouncement—score 61 - 2026-03-241mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) On March 20, 2026, Mary Wilcox informed Solventum Corporation (the “Company”) of her intent to retire and resign from her position as Chief Accounting Officer of the Company following a search for and appointment of her successor.
executive changeneutralscore 20 - 2026-02-262mo agoItem 2.02
hereof) 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded in the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. SOLVENTUM CORPORATION By: /s/ Matthew M. Rice Matthew M. Rice Vice President, Associate General Counsel & Assistant Secretary Dated: February 26, 2026
earnings preannouncementnegativescore 15 - 2025-10-216mo agoItem 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 21, 2025, Solventum Corporation (the “Company”) announced that Heather Knight has been appointed to serve in the newly created role of Chief Commercial Officer of the Company, effective as of November 10, 2025. Ms. Knight will oversee all global commercial and R&D operations across the Company’s MedSurg, Dental Solutions and Health Infor…
executive changeneutralscore 1
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.